Rathbone Brothers plc bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,796 shares of the life sciences company’s stock, valued at approximately $312,000.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Illumina by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock worth $1,646,479,000 after buying an additional 285,379 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Illumina by 8.0% in the 1st quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock worth $248,460,000 after buying an additional 107,941 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in shares of Illumina by 40.1% in the 1st quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock worth $161,787,000 after buying an additional 271,461 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Illumina by 2.5% in the 2nd quarter. Legal & General Group Plc now owns 667,874 shares of the life sciences company’s stock worth $115,892,000 after buying an additional 16,560 shares in the last quarter. Finally, Swiss National Bank raised its holdings in shares of Illumina by 2.7% in the 2nd quarter. Swiss National Bank now owns 534,445 shares of the life sciences company’s stock worth $92,737,000 after buying an additional 13,900 shares in the last quarter. 93.34% of the stock is owned by institutional investors and hedge funds.
In related news, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $174.24, for a total value of $25,264.80. Following the sale, the senior vice president now owns 10,646 shares of the company’s stock, valued at $1,854,959.04. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Michel Bouchard sold 246 shares of the business’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $185.00, for a total transaction of $45,510.00. Following the completion of the sale, the insider now directly owns 18,893 shares in the company, valued at approximately $3,495,205. The disclosure for this sale can be found here. In the last three months, insiders sold 167,705 shares of company stock worth $31,544,118. 1.60% of the stock is currently owned by insiders.
A number of equities analysts have recently issued reports on ILMN shares. Deutsche Bank AG set a $175.00 target price on Illumina and gave the stock a “hold” rating in a report on Friday, July 28th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and increased their target price for the stock from $170.00 to $215.00 in a report on Monday, August 7th. Morgan Stanley reissued an “underweight” rating and issued a $122.00 target price (up from $115.00) on shares of Illumina in a report on Monday, July 10th. Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a report on Wednesday, June 21st. Finally, Barclays PLC reissued a “hold” rating and issued a $150.00 target price on shares of Illumina in a report on Wednesday, July 19th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $177.01.
ILLEGAL ACTIVITY WARNING: “Rathbone Brothers plc Buys Shares of 1,796 Illumina, Inc. (ILMN)” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/09/10/rathbone-brothers-plc-buys-shares-of-1796-illumina-inc-ilmn.html.
Illumina, Inc. (NASDAQ:ILMN) opened at 209.68 on Friday. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $211.27. The company has a market capitalization of $30.61 billion, a price-to-earnings ratio of 42.07 and a beta of 0.81. The stock has a 50 day moving average price of $192.45 and a 200 day moving average price of $178.64.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662 million for the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter in the previous year, the firm posted $0.86 earnings per share. Illumina’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current fiscal year.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.